Abstract

My laboratory aims to understand epigenetic mechanisms that govern gene expression during development and tumorigenesis. An emerging class of drugs - epigenetic modifiers, or ‘epidrugs’ - hold great promise in oncology. Designing epidrugs with high efficacy, while excluding potential side effects on the epigenome, remains a challenge. We have developed a highly multiplexed, quantitative method for systematically profiling the interaction of drugs with the epigenome in human cell lines, primary cells, as well as fixed material. I will discuss the development of the methodology as well as emerging applications.